Table 7.
Incidence (n, %) of Potentially Clinically Significant Shifts in Vital Signs from Normal at Baseline to End of Treatment (Safety Analysis Set)
| Shift to high, n (%) | |||||
|---|---|---|---|---|---|
| Quetiapine XR (n=92) | Placebo (n=100) | ||||
| Parameter | Thresholds for potentially significant shift | n (%) | Na | n (%) | Na |
| SBP | ≥20 mmHg decrease from supine to standing | 0 (0) | 92 | 0 (0) | 100 |
| DBP | ≥20 mmHg decrease from supine to standing | 0 (0) | 92 | 1 (1.0) | 100 |
| Pulse | ≥20 bpm increase from supine to standing | 5 (5.4) | 92 | 9 (9.0) | 100 |
a
N, number of patients with available data at baseline and end-of-treatment assessments.
SBP, systolic blood pressure; DBP, diastolic blood pressure; bpm, beats per minute.